EVOCAL Health has been selected among top-tier digital health companies from around the world and has successfully cooperated with the prestigious U.S. accelerator PharmStars.
©m:con/Ben van Skyhawk
Boston/Hamburg (USA/Germany), December 20, 2021: The prestigious US-based accelerator PharmStars that is focused on innovative technologies, products and services in the context of biopharmaceutical research and development, selected 12 digital health companies from around the world to participate in the innovation acceleration program after an international application period.
The Hamburg-based company EVOCAL Health has been selected as the first German digital health company. PharmStars' mission is to connect pharmaceutical companies with leading digital health startups and bridge the "pharma startup gap". PharmStars' six member companies include leading pharmaceutical companies such as Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, and Sumitovant Biopharma, among others.
The award-winning German health company has developed a platform technology that can be used to develop prognostic models for the detection and treatment of cardiovascular, respiratory and neurodegenerative or mental diseases. In clinical research and development, the Vocal biomarker technology helps to generate a more comprehensive picture of a patient's disease progression and to better and faster understand the human body's response to certain treatment or medical intervention in decentralized clinical trials and remote patient care.
EVOCAL Health Co-Founder & CEO/COO Philip Mertes explains: "The US market is market is of utmost importance to us as the U.S. represent the largest homogeneous market in the western world and is pioneering innovations. As a German company with international ambitions, we are proud that our work has received worldwide recognition and that we were able to take an important step into the U.S. market together with PharmStars. PharmStars is dedicated to prepare leading pharma and best-in-class digital health companies around the world to leverage each other’s strengths and accelerate successful partnerships.”
PharmStars is the member-based, pharma-focused accelerator for digital health startups. Through our extensive expertise across pharma, startups, digital health, and innovation, we understand the challenges that pharma and startups face when seeking to collaborate. Our PharmaUTM program supports digital health startups and our pharma members in “bridging the gap,” leading to greater success and faster adoption of “beyond the molecule” solutions for patients.